Biotech Goes Sky-High After LSD Drug Treats Depression
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Biotech Goes Sky-High After LSD Drug Treats Depression" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, Fierce Biotech, Business Wire and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 140d ago.
Quick answers
Why is "Biotech Goes Sky-High After LSD Drug Treats Depression" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results Yahoo Finance · 142d ago
- Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says Fierce Biotech · 142d ago
- Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 Business Wire · 142d ago
- Definium's LSD-based depression pill delivers strong late-stage results, shares surge Reuters · 142d ago
- Biotech Goes Sky-High After LSD Drug Treats Depression Investor's Business Daily · 142d ago
Topics
Related trends
Nebrasketball Goes to Uncasville, Leaves with Win Over Providence
Nebraska basketball defeats Providence 67-58 in a neutral-site matchup at Mohegan Sun in Uncasville, securing an early-season resume win.
Berkshire After Buffett: Steady Hands, Big Bets In The Greg Abel Era
Market analysts focus on Greg Abel's upcoming 13F filing and portfolio strategy at Berkshire Hathaway.
After the US midterm rout of Trumpism, the world struggles to trust America again
Democrats won control of both houses of Congress in a midterm rout of Trumpism, but global leaders and citizens say one election does not restore trust in America.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.